is pleased to announce that the patented strain of Bacillus subtilis PB6, CLOSTATTM
, has received an extension from the European Commission (Regulation (EU) N° 168/2011) allowing it to be used in combination with four additional coccidiostats, increasing its total compatibility to nine coccidiostats. This extension was granted after a positive assessment by the European Food Safety Authority (EFSA) and approved by the Standing Committee on the Food Chain and Animal Health.
After a series of in vitro and in vivo studies, EU authorities concluded that the unique strain of Bacillus subtilis PB6 can now also be used in combination with maduramycin ammonium, monensin sodium, narasin, and robenidine hydrochloride approved coccidiostats in the EU. Since CLOSTAT was approved by the European Commission in February 2010, it has been compatible for use with diclazuril, decoquinate, salinomycin sodium, narasin/nicarbazin, and lasalocid sodium approved coccidiostats.
This extension provides veterinarians, nutritionists, and poultry producers with more flexibility when searching for the best solutions to manage both coccidiosis and bacterial enteritis in their flocks. CLOSTAT is a natural alternative that supports animal health by maintaining a balanced gastro intestinal tract. CLOSTAT is patented for its unique and already demonstrated efficacy in reducing mortality and lesion scores due to necrotic enteritis because of its targeted activity against Clostridium spp.1 With this approval, Kemin gives broiler producers extra flexibility on the use of CLOSTAT in combination with different coccidiostats in their feed.